Autoimmune Disease Treatment Market Research Information: By Disease Type (Localized, Systemic), Diagnosis (Elisa, Dot Blot, Agglutination, Others), Therapeutic Products (Drugs, Monitoring Equipment), Distribution Channel – Global Forecast Till 2023
ID: MRFR/Pharma/4137-HCR | February 2021 | Region: Global | 85 pages
Market Scenario:
An autoimmune disease is a condition in which body's immune system destroys its own body tissue. There are more than 80 different type of autoimmune disorders but the most common are multiple sclerosis, IBD, diabetes, rheumatoid arthritis, psoriasis, and others. Autoimmune disease may result in abnormal growth of an organ, the destruction of body tissue, and changes in organ function
According to the National Institutes of Health (NIH), around 23.5 million Americans are suffering from autoimmune disease. NIH has also estimated that the annual direct health care costs for autoimmune disease are near to the USD 100 billion. Whereas for cancers, and heart & strokes, the cost is around USD 57 billion, and USD 200 billion respectively.
Notably, growing public awareness, and the increasing prevalence of autoimmune diseases, and other related complications are the key factors driving the autoimmune disease treatment market. Government and other different private associations have started educating people about diseases through seminars, and conferences. For instance, the American Autoimmune Related Diseases Association in collaboration with the National Coalition of Autoimmune Patient Groups conducts a program, named Autoimmune Research Network (ARNet). Through this research network, researchers empowers patients by supporting their participation in research on autoimmune diseases by gathering patient information. This information is majorly helpful during clinical trials.
Various other factors such as technological advancements, unmet medical needs, increasing government assistance, rising prevalence of co-existing disorders, improving regulatory framework, improving funding and reimbursement policies, and increasing adoption rate, are continuously contributing towards the growth of the global autoimmune disease treatment market.
Despite these drivers, there are some issues associated with autoimmune disease treatment market. High cost of treatment, presence of misbranded drugs, side-effects of treatment, and poor healthcare system in low or middle-income countries, may hamper the growth of the market.
It is estimated that the autoimmune disease treatment market is expected to grow at a CAGR 11.2% during the forecast period of 2017-2023.
Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation
Intended Audience
- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Diagnostic Laboratories
- Government Research Institute
- Academic Institutes and Universities
Segmentation
The global autoimmune disease treatment market is segmented on the basis of disease type, diagnosis, therapeutic products, and distribution channels.
On the basis of the disease type, the market is classified as localized, and systemic. The localized segment is further classified into multiple sclerosis, inflammatory bowel disease, diabetes, and other. The systemic segment is further classified into rheumatoid arthritis, psoriasis, lupus, and others.
On the basis of the diagnosis, the market is classified as ELISA, dot blot, line blot, agglutination, double immune diffusion, western blotting, multiplex immunoassay, and others.
On the basis of the therapeutic products, the market is classified as drugs, and therapeutic and monitoring equipment. The drugs segment is further segmented into biologics, immunosuppressant, anti-inflammatory drugs, corticosteroids, and non-steroidal anti-inflammatory drugs.
On the basis of the distribution channel, the market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.
Regional Analysis
The Americas dominate the autoimmune disease treatment market owing to the rising cases of autoimmune diseases, and high healthcare expenditure. As per the data suggested by Centers for Disease Control and Prevention in 2015, the total healthcare expenditure in the U.S. was reported to be USD 3.2 trillion, whereas, hospital care accounted for a share of 32.3%.
Europe holds the second position in the autoimmune disease treatment market. It is expected that the financial support provided by the government bodies for research & development and amendments in reimbursement policies in the healthcare is likely to drive the European market
Owing to a huge patient pool and developing healthcare technology, Asia Pacific is the fastest growing autoimmune disease treatment market. Healthcare expenditure is also found to be escalating in various Asia Pacific countries. The Australian Institute of Health and Welfare suggested that in the year 2015-2016, the total healthcare expenditure was USD 170.4 billion, which is around 3.6% higher than the expenditure during 2014-2015.
The Middle East & Africa holds the lowest market due to poor medical facilities, and lack of technical knowledge.
Key Players
Some of key the players in the global autoimmune disease treatment market are Abbott Laboratories, Amgen Inc., Genentech Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bio-Rad, Chugai Pharmaceutical Co. Ltd., Danaher, Elan Corporation Plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, HYCOR Biomedical, Johnson & Johnson Inc., Merck & Co. Inc., Siemens, Squibb Company, Thermo Fisher Scientific, and others.
Frequently Asked Questions (FAQ) :
Autoimmune diseases occur when the body’s immune system mistakes the body’s own tissue for foreign objects and starts attacking it.
The market is expected to exhibit a strong 11.2% CAGR over the forecast period from 2017 to 2023.
The growing prevalence of autoimmune diseases is the major drive for the market.
The Americas dominate the global autoimmune disease treatment market.
Leading players in the autoimmune disease treatment market include Abbott, Amgen, and Bayer, among others.
Autoimmune diseases occur when the body’s immune system mistakes the body’s own tissue for foreign objects and starts attacking it.
The market is expected to exhibit a strong 11.2% CAGR over the forecast period from 2017 to 2023.
The growing prevalence of autoimmune diseases is the major drive for the market.
The Americas dominate the global autoimmune disease treatment market.
Leading players in the autoimmune disease treatment market include Abbott, Amgen, and Bayer, among others.
Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Autoimmune Disease Treatment Market, by Disease type
6.1 Introduction
6.2 Localized
6.2.1 Market Estimates & Forecast, 2016 – 2023
6.3 Systemic
6.3.1 Market Estimates & Forecast, 2016 – 2023
Chapter 7. Global Autoimmune Disease Treatment Market, by Diagnosis
7.1 Introduction
7.2 ELISA
7.2.1 Market Estimates & Forecast, 2017 – 2023
7.3 Dot blot
7.3.1 Market Estimates & Forecast, 2017 – 2023
7.4 Line blot
7.4.1 Market Estimates & Forecast, 2017 – 2023
7.5 Agglutination
7.5.1 Market Estimates & Forecast, 2017 – 2023
7.6 Double immune diffusion
7.6.1 Market Estimates & Forecast, 2017 – 2023
7.7 Western Blotting
7.7.1 Market Estimates & Forecast, 2017 – 2023
7.8 Multiplex immunoassay
7.8.1 Market Estimates & Forecast, 2017 – 2023
7.9 Others
7.9.1 Market Estimates & Forecast, 2017 – 2023
Chapter 8. Global Autoimmune Disease Treatment Market, by Therapeutic Products
8.1 Introduction
8.2 Drugs
8.2.1 Market Estimates & Forecast, 2017 – 2023
8.3 Therapeutic and Monitoring Equipment
8.3.1 Market Estimates & Forecast, 2017 – 2023
Chapter 9. Global Autoimmune Disease Treatment Market, by Distribution Channel
9.1 Introduction
9.2 Hospitals & Clinics
9.2.1 Market Estimates & Forecast, 2017 – 2023
9.3 Diagnostic Centers
9.3.1 Market Estimates & Forecast, 2017 – 2023
9.4 Drug Stores
9.4.1 Market Estimates & Forecast, 2017 – 2023
9.5 Pharmacies
9.5.1 Market Estimates & Forecast, 2017 – 2023
9.6 Others
9.6.1 Market Estimates & Forecast, 2017 – 2023
Chapter 10. Global Autoimmune Disease Treatment Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.1 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 U.K
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa
Chapter 11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
Chapter 12 Company Profiles
12.1 Abbott Laboratories
12.1.1 Company Overview
12.1.2 Disease type of Causative Agents Overview
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 Amgen Inc.
12.2.1 Company Overview
12.2.2 Disease type of Causative Agents Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Bayer Schering Pharma AG
12.3.1 Company Overview
12.3.2 Disease type of Causative Agents Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Danaher
12.4.1 Company Overview
12.4.2 Disease type of Causative Agents/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Elan Corporation Plc
12.5.1 Company Overview
12.5.2 Disease type of Causative Agents Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.6 Eli Lilly and Company
12.6.1 Company Overview
12.6.2 Disease type of Causative Agents Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 F. HOFFMANN-LA ROCHE AG
12.7.1 Overview
12.7.2 Disease type of Causative Agents Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Others
Chapter 13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Autoimmune Disease Treatment Industry
Chapter 14 Appendix
LIST OF TABLES
Table 1 Autoimmune Disease Treatment Industry Synopsis, 2017 – 2023
Table 2 Autoimmune Disease Treatment Market Estimates and Forecast, 2017 – 2023, (USD Million)
Table 3 Autoimmune Disease Treatment Market by Region, 2017 – 2023, (USD Million)
Table 4 Autoimmune Disease Treatment Market by Disease type, 2017 – 2023, (USD Million)
Table 5 Autoimmune Disease Treatment Market by Diagnosis, 2017 – 2023, (USD Million)
Table 6 Autoimmune Disease Treatment Market by Therapeutic Products, 2017 – 2023, (USD Million)
Table 7 Autoimmune Disease Treatment Market by Distribution Channels, 2017 – 2023, (USD Million)
Table 8 North America Autoimmune Disease Treatment Market by Disease type, 2017 – 2023, (USD Million)
Table 9 North America Autoimmune Disease Treatment Market by Diagnosis, 2017 – 2023, (USD Million)
Table 10 North America Autoimmune Disease Treatment Market by Therapeutic Products, 2017 – 2023, (USD Million)
Table 11 North America Autoimmune Disease Treatment Market by Distribution Channels, 2017 – 2023, (USD Million)
Table 12 US Autoimmune Disease Treatment Market by Disease type, 2017 – 2023, (USD Million)
Table 13 US Autoimmune Disease Treatment Market by Diagnosis, 2017 – 2023, (USD Million)
Table 14 US Autoimmune Disease Treatment Market by Therapeutic Products, 2017 – 2023, (USD Million)
Table 15 US Autoimmune Disease Treatment Market by Distribution Channels, 2017 – 2023, (USD Million)
Table 16 Canada Autoimmune Disease Treatment market by Disease type, 2017 – 2023, (USD Million)
Table 17 Canada Autoimmune Disease Treatment Market by Diagnosis, 2017 – 2023, (USD Million)
Table 18 Canada Autoimmune Disease Treatment Market by Therapeutic Products, 2017 – 2023, (USD Million)
Table 19 Canada Autoimmune Disease Treatment market by Distribution Channels, 2017 – 2023, (USD Million)
Table 20 South America Autoimmune Disease Treatment Market by Disease type, 2017 – 2023, (USD Million)
Table 21 South America Autoimmune Disease Treatment Market by Diagnosis, 2017 – 2023, (USD Million)
Table 22 South America Autoimmune Disease Treatment Market by Therapeutic Products, 2017 – 2023, (USD Million)
Table 23 South America Autoimmune Disease Treatment Market by Distribution Channels, 2017 – 2023, (USD Million)
Table 24 Europe Autoimmune Disease Treatment Market by Disease type, 2017 – 2023, (USD Million)
Table 25 Europe Autoimmune Disease Treatment Market by Diagnosis, 2017 – 2023, (USD Million)
Table 26 Europe Autoimmune Disease Treatment Market by Therapeutic Products, 2017 – 2023, (USD Million)
Table 27 Europe Autoimmune Disease Treatment Market by Distribution Channels, 2017 – 2023, (USD Million)
Table 28 Western Europe Autoimmune Disease Treatment Market by Disease type, 2017 – 2023, (USD Million)
Table 29 Western Europe Autoimmune Disease Treatment Market by Diagnosis, 2017 – 2023, (USD Million)
Table 30 Western Europe Autoimmune Disease Treatment Market by Therapeutic Products, 2017 – 2023, (USD Million)
Table 31 Western Europe Autoimmune Disease Treatment Market by Distribution Channels, 2017 – 2023, (USD Million)
Table 32 Eastern Europe Autoimmune Disease Treatment market by Disease type, 2017 – 2023, (USD Million)
Table 33 Eastern Europe Autoimmune Disease Treatment Market by Diagnosis, 2017 – 2023, (USD Million)
Table 34 Eastern Europe Autoimmune Disease Treatment Market by Therapeutic Products, 2017 – 2023, (USD Million)
Table 35 Eastern Europe Autoimmune Disease Treatment Market by Distribution Channels, 2017 – 2023, (USD Million)
Table 36 Asia Pacific Autoimmune Disease Treatment Market by Disease type, 2017 – 2023, (USD Million)
Table 37 Asia Pacific Autoimmune Disease Treatment Market by Diagnosis, 2017 – 2023, (USD Million)
Table 38 Asia Pacific Autoimmune Disease Treatment Market by Therapeutic Products, 2017 – 2023, (USD Million)
Table 39 Asia Pacific Autoimmune Disease Treatment market by Distribution Channels, 2017 – 2023, (USD Million)
Table 40 The Middle East & Africa Autoimmune Disease Treatment Market by Disease type, 2017 – 2023, (USD Million)
Table 41 The Middle East & Africa Autoimmune Disease Treatment Market by Diagnosis, 2017 – 2023, (USD Million)
Table 42 The Middle East & Africa Autoimmune Disease Treatment Market by Therapeutic Products, 2017 – 2023, (USD Million)
Table 43 The Middle East & Africa Autoimmune Disease Treatment market by Distribution Channels, 2017 – 2023, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Autoimmune Disease Treatment Market
Figure 3 Segmentation Market Dynamics for Autoimmune Disease Treatment Market
Figure 4 Global Autoimmune Disease Treatment market Share, by Disease type 2016
Figure 5 Global Autoimmune Disease Treatment market Share, by Diagnosis 2016
Figure 6 Global Autoimmune Disease Treatment market Share, by Therapeutic Products 2016
Figure 7 Global Autoimmune Disease Treatment market Share, by Distribution Channels, 2016
Figure 8 Global Autoimmune Disease Treatment market Share, by Region, 2016
Figure 9 North America Autoimmune Disease Treatment market Share, by Country, 2016
Figure 10 Europe Autoimmune Disease Treatment market Share, by Country, 2016
Figure 11 Asia Pacific Autoimmune Disease Treatment market Share, by Country, 2016
Figure 12 Middle East & Africa Autoimmune Disease Treatment market Share, by Country, 2016
Figure 13 Global Autoimmune Disease Treatment market: Company Share Analysis, 2016 (%)
Figure 14 Abbott Laboratories: Key Financials
Figure 15 Abbott Laboratories Segmental Revenue
Figure 16 Abbott Laboratories: Geographical Revenue
Figure 17 Amgen Inc.: Key Financials
Figure 18 Amgen Inc.: Segmental Revenue
Figure 19 Amgen Inc.: Geographical Revenue
Figure 20 Bayer Schering Pharma AG: Key Financials
Figure 21 Bayer Schering Pharma AG: Segmental Revenue
Figure 22 Bayer Schering Pharma AG: Geographical Revenue
Figure 23 Danaher: Key Financials
Figure 24 Danaher: Segmental Revenue
Figure 25 Danaher: Geographical Revenue
Figure 26 Elan Corporation Plc: Key Financials
Figure 27 Elan Corporation Plc: Segmental Revenue
Figure 28 Elan Corporation Plc Geographical Revenue
Figure 29 Eli Lilly and Company: Key Financials
Figure 30 Eli Lilly and Company: Segmental Revenue
Figure 31 Eli Lilly and Company: Geographical Revenue
Figure 32 F. HOFFMANN-LA ROCHE AG: Key Financials
Figure 33 F. HOFFMANN-LA ROCHE AG: Segmental Revenue
Figure 34 F. HOFFMANN-LA ROCHE AG: Geographical Revenue
